amgen glp 1 drug Development Progress and Prospects of Antibody-Peptide Conjugates Redefining Obesity Care: The GLP-1

Germany, the UK, France, and Scandinavia are the primary European GLP-1 markets, with strong diabetes prescribing supported by national guideline recommendations and health insurance coverage

Insurance coverage remains unpredictable for weight loss medications, with many plans requiring prior authorization or denying coverage entirely

Beinaglutide was approved in China in 2016 for T2DM and also reduced BMI in overweight patients [13]

MAPK: mitogen-activated protein kinases

F.et al (2000)

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE/ mice